Xtant Medical (XTNT) Expected to Announce Quarterly Earnings on Monday

Xtant Medical (NYSEAMERICAN:XTNT) will likely be announcing its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of ($0.02) per share and revenue of $24.8760 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its earnings results on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $20.88 million for the quarter, compared to analysts’ expectations of $20.16 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Xtant Medical Stock Down 0.6%

Shares of NYSEAMERICAN XTNT opened at $0.43 on Friday. The stock has a market capitalization of $60.28 million, a P/E ratio of 43.02 and a beta of -0.16. The company has a 50-day moving average price of $0.44 and a 200-day moving average price of $0.52. Xtant Medical has a 1 year low of $0.39 and a 1 year high of $0.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.34 and a quick ratio of 1.64.

Institutional Investors Weigh In On Xtant Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC boosted its holdings in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after acquiring an additional 57,000,000 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Xtant Medical by 28.8% in the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after acquiring an additional 205,945 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares during the last quarter. Wiregrass Investment Management LLC purchased a new stake in shares of Xtant Medical in the fourth quarter valued at about $81,000. Finally, Mink Brook Asset Management LLC lifted its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares in the last quarter. 69.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, BTIG Research restated a “buy” rating and issued a $1.00 target price on shares of Xtant Medical in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $1.00.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.